# An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer

> **NCT02939274** · PHASE2 · UNKNOWN · sponsor: **Rogers Sciences Inc.** · enrollment: 15 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Verteporfin
- **DEVICE:** Continuous Low-Irradiance Photodynamic Therapy (CLIPT)

## Key facts

- **NCT ID:** NCT02939274
- **Lead sponsor:** Rogers Sciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2018-12
- **Final completion:** 2019-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2018-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02939274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02939274, "An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02939274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*